AstraZeneca, Daiichi Sankyo secure FDA approval for Enhertu in two early breast cancer indications

AstraZeneca PLC (LSE: AZN; NASDAQ: AZN) and Daiichi Sankyo Company, Limited (TYO: 4568) have secured United States Food and Drug Administration approval for Enhertu in two new HER2-positive early breast cancer indications, moving the antibody drug conjugate deeper into the curative-intent treatment setting. The approval covers neoadjuvant use before surgery in Stage II or Stage III HER2-positive breast cancer and adjuvant use after surgery in patients with residual invasive disease following prior trastuzumab-based and taxane-based treatment. The decision materially expands the commercial and clinical relevance of Enhertu because early breast cancer represents a different strategic category from metastatic disease, with treatment decisions shaped by cure potential, recurrence risk, safety tolerance and long-term sequencing. For AstraZeneca and Daiichi Sankyo, the approval strengthens one of the most important antibody drug conjugate franchises in oncology and gives both companies a stronger claim to leadership in HER2-directed therapy.

Why does the FDA approval of Enhertu in early HER2-positive breast cancer matter for AstraZeneca and Daiichi Sankyo?

The FDA approval matters because Enhertu is no longer being positioned only as a treatment for advanced or metastatic HER2-expressing disease. By entering both the neoadjuvant and adjuvant settings, AstraZeneca and Daiichi Sankyo are pushing the drug into an earlier treatment window where the clinical objective is not merely disease control but long-term recurrence prevention. That shift changes the strategic profile of Enhertu because early-stage breast cancer treatment often influences physician habits, guideline pathways and patient journeys for years.

In the neoadjuvant setting, the FDA approved Enhertu followed by a taxane, trastuzumab and pertuzumab for adult patients with HER2-positive Stage II or Stage III breast cancer. In the adjuvant setting, Enhertu was approved for adult patients with HER2-positive breast cancer who still have residual invasive disease after treatment with trastuzumab, with or without pertuzumab, and taxane-based therapy. That second setting is especially important because residual disease after pre-surgical therapy is a high-risk clinical signal, and oncologists are often looking for stronger post-surgery options to reduce recurrence risk.

For AstraZeneca, the decision supports its broader oncology strategy of building durable franchises around high-value targeted therapies rather than relying on one-off indications. For Daiichi Sankyo, the approval validates the company’s antibody drug conjugate platform and strengthens the economics of its 2019 collaboration with AstraZeneca. The release also stated that AstraZeneca will make milestone payments of $155 million to Daiichi Sankyo following the United States approvals, while United States sales are recognized by Daiichi Sankyo under the collaboration structure.

How strong were the DESTINY-Breast11 and DESTINY-Breast05 data behind the FDA decision?

The regulatory case was anchored by two Phase III studies, DESTINY-Breast11 for neoadjuvant use and DESTINY-Breast05 for adjuvant use. In DESTINY-Breast11, Enhertu followed by taxane, trastuzumab and pertuzumab produced a pathologic complete response rate of 67.3%, compared with 56.3% for dose-dense doxorubicin and cyclophosphamide followed by taxane, trastuzumab and pertuzumab. That represented an 11.2 percentage-point improvement, with statistical significance reported in the trial.

The neoadjuvant result is strategically important because pathologic complete response is often used as an early indicator of deeper treatment activity before longer-term event-free survival data fully mature. The study had relatively few event-free survival and overall survival events at the time of the pathologic complete response analysis, which means the approval gives clinicians an earlier efficacy signal while the longer-term outcome picture continues to develop. This is where adoption will depend not only on headline response rates, but also on how oncologists weigh treatment sequencing, toxicity management and patient selection.

DESTINY-Breast05 may be even more commercially consequential because it directly addresses the post-neoadjuvant residual disease population. Enhertu reduced the risk of invasive disease recurrence or death by 53% compared with trastuzumab emtansine, with a hazard ratio of 0.47. At three years, 92.4% of patients in the Enhertu arm were alive and free of invasive disease, compared with 83.7% in the trastuzumab emtansine arm. That is the kind of gap that can influence guidelines, hospital pathways and payer discussions, although real-world use will still depend on patient suitability and adverse event monitoring.

What does this approval signal about the antibody drug conjugate race in oncology?

Enhertu’s expansion into early breast cancer reinforces the broader shift in oncology from late-line metastatic use toward earlier, higher-impact treatment settings. Antibody drug conjugates were once viewed mainly as sophisticated options for patients who had exhausted several prior therapies. The latest Enhertu approval shows how the category is maturing into a frontline and curative-intent battleground, especially when efficacy signals are strong enough to challenge entrenched standards of care.

For competitors, the message is uncomfortable but clear. The next phase of the antibody drug conjugate market will not be won simply by showing tumor shrinkage in heavily pretreated disease. Companies will need to prove that their drugs can alter recurrence risk, fit into established multimodal treatment regimens and demonstrate acceptable safety in patients who may otherwise have curable disease. That is a higher bar, because early-stage patients and physicians often have less tolerance for severe or irreversible toxicities.

The approval also strengthens the competitive moat around AstraZeneca and Daiichi Sankyo’s HER2 franchise. Enhertu is already approved in more than 95 countries for HER2-positive metastatic breast cancer, and its United States label includes multiple HER2-driven or HER2-expressing cancer settings. Moving into early HER2-positive breast cancer gives the companies a broader lifecycle strategy at a time when large pharmaceutical groups are aggressively competing for differentiated oncology assets. In plain English, this is not just another label expansion. It is a land grab in the treatment sequence.

What safety questions could shape physician and payer adoption after the FDA approval?

The main adoption risk remains safety, especially interstitial lung disease and pneumonitis, which are closely watched adverse events for Enhertu. The companies said no new safety concerns were identified in DESTINY-Breast11 or DESTINY-Breast05. However, safety tolerance can differ meaningfully between metastatic and early-stage disease because early-stage patients may have longer survival expectations and may be receiving treatment with curative intent.

In DESTINY-Breast11, Enhertu followed by taxane, trastuzumab and pertuzumab showed similar rates of overall drug-related adverse events and interstitial lung disease or pneumonitis compared with the dose-dense chemotherapy comparator regimen. The release also said the Enhertu regimen had lower rates of Grade 3 or higher adverse events, serious adverse events, treatment interruptions, left ventricular dysfunction and hematological toxicities. That profile could help the neoadjuvant case if physicians see the regimen as both effective and manageable.

DESTINY-Breast05 presents a more nuanced safety picture. Enhertu and trastuzumab emtansine showed similar rates of overall drug-related adverse events and Grade 3 or higher adverse events, but adjudicated drug-related interstitial lung disease or pneumonitis occurred in 9.6% of patients in the Enhertu arm compared with 1.6% in the trastuzumab emtansine arm. Most events were low grade, but the Enhertu arm included seven Grade 3 events and two Grade 5 deaths. That does not negate the efficacy signal, but it does mean physicians, payers and regulators will continue watching risk mitigation closely as use expands.

How could the new Enhertu approval affect AstraZeneca stock and Daiichi Sankyo investor sentiment?

AstraZeneca shares have already had a strong twelve-month run, with London Stock Exchange data showing a 52-week range of 9,651p to 15,732p and Financial Times market data showing the stock closed at 13,632p on Friday, 15 May 2026, below its February 2026 high. That places AstraZeneca in a position where investors are likely to view the Enhertu approval as strategically supportive rather than as a single-day rerating event. The stock already reflects confidence in AstraZeneca’s oncology depth, but earlier-stage Enhertu approvals strengthen the medium-term revenue durability story.

For Daiichi Sankyo, the market setup is different. Recent market data show Daiichi Sankyo trading much closer to the lower end of its 52-week range of ¥2,443 to ¥4,178, with market capitalization around the ¥4.7 trillion to ¥4.9 trillion range across available sources. That weaker share-price backdrop makes the Enhertu approval more important for sentiment because it reinforces the value of Daiichi Sankyo’s antibody drug conjugate engine at a time when investors have been more cautious on the stock.

The split in investor interpretation is worth noting. AstraZeneca investors may see the approval as one more brick in a large oncology wall. Daiichi Sankyo investors may see it as a more direct validation of platform economics, pipeline credibility and future milestone leverage. Both readings can be true. The approval is strategically important for both companies, but the sentiment impact may be more visible for Daiichi Sankyo if investors begin to reassess the durability of its oncology growth profile.

What happens next for Enhertu as AstraZeneca and Daiichi Sankyo move deeper into early breast cancer?

The next phase will be less about approval headlines and more about treatment adoption. United States oncologists now have a broader Enhertu label in HER2-positive early breast cancer, but practice change depends on guideline integration, institutional pathway updates, payer coverage, physician confidence and safety monitoring. The release noted that based on DESTINY-Breast05, trastuzumab deruxtecan has already been included in National Comprehensive Cancer Network guidelines as a Category 1 recommended treatment in the adjuvant setting for HER2-positive early breast cancer with residual disease and high recurrence risk after preoperative therapy.

The international dimension also matters. The United States submissions were reviewed under Project Orbis, and separate regulatory applications are under review in other countries. If additional markets follow the FDA’s lead, Enhertu’s early-stage opportunity could become a global growth driver rather than a United States-only catalyst. That would support the broader commercial thesis behind AstraZeneca and Daiichi Sankyo’s collaboration.

The bigger question is whether Enhertu becomes a foundational therapy across HER2-positive breast cancer or remains selectively used in higher-risk early-stage populations. The DESTINY-Breast05 data provide a powerful case in residual disease after neoadjuvant therapy. The neoadjuvant setting may require more careful interpretation as longer-term survival data mature. Either way, the strategic direction is unmistakable: AstraZeneca and Daiichi Sankyo are trying to move Enhertu from a later-line oncology success story into the architecture of early breast cancer treatment.

Key takeaways on what Enhertu’s FDA approval means for AstraZeneca, Daiichi Sankyo and the ADC market

• AstraZeneca and Daiichi Sankyo have moved Enhertu into two United States early HER2-positive breast cancer indications, expanding the drug beyond metastatic disease.
• The approval shifts Enhertu into the curative-intent setting, where treatment decisions are shaped by recurrence prevention and long-term outcomes.
• DESTINY-Breast11 showed a higher pathologic complete response rate for Enhertu followed by taxane, trastuzumab and pertuzumab versus the chemotherapy-based comparator regimen.
• DESTINY-Breast05 delivered the more commercially forceful result, with a 53% reduction in the risk of invasive disease recurrence or death versus trastuzumab emtansine.
• Safety monitoring remains central, particularly because interstitial lung disease and pneumonitis are more consequential in early-stage treatment settings.
• AstraZeneca gains another strategic oncology catalyst, but the stock already reflects strong investor confidence in its broader pipeline.
• Daiichi Sankyo may see greater sentiment leverage from the approval because Enhertu remains central to the market’s view of its antibody drug conjugate platform.
• The approval raises the competitive bar for antibody drug conjugates by showing that the category can move from late-line disease into earlier treatment pathways.
• International regulatory decisions will determine whether the United States approval becomes a global commercial inflection point.
• The main execution test is no longer whether Enhertu has compelling data, but whether physicians, payers and treatment guidelines adopt it broadly enough to reshape standard care.